86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

32 trials found

diseases per page:

Showing 1 to 10 of 32 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05427162 (ClinicalTrials.gov)	June 21, 2022	16/6/2022	A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist	Open-Label, Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Mu ...	Pulmonary Arterial Hypertension	Drug: Prostacyclin Receptor Agonist	Actelion	NULL	Recruiting	18 Years	55 Years	All	86	Phase 1	United States
2	JPRN-UMIN000025176	2017/01/01	15/12/2016	Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmon ...	Efficacy, tolerability, and safety of transition from beraprost to selexipag in patients with pulmon ...	Pulmonary arterial hypertension	Medicine transition from beraprostto selexipag In accordance with the Japanese package insert (http:/ ...	Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	33	Not selected	Japan
3	EUCTR2016-003495-53-NL (EUCTR)	29/11/2016	15/12/2016	Study on the effect of the drug selexipag in adult patients with elevated pressure in the pulmonary ...	Prostacyclinreceptor agonist Selexipag in patients with pulmonary arterial hypertension and congenit ...	Pulmonary arterial hypertension related to congenital heart disease.;Therapeutic area: Diseases [C] ...	Trade Name: Selexipag Product Name: Selexipag	Academic Medical Center - Cardiology	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 3	Netherlands
4	NCT02436512 (ClinicalTrials.gov)	June 2015	13/4/2015	Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide	A Phase 3 Open-label Multi-Center, Two-Part Single-arm Study to Evaluate the Acute Vasodilation Resp ...	Pulmonary Arterial Hypertension	Drug: Inhaled Nitric Oxide	Geno LLC	NULL	Withdrawn	18 Years	70 Years	Both	0	Phase 3	United States
5	JPRN-JapicCTI-142722	01/1/2015	27/11/2014	ACT-385781A extension study for PAH pediatric patients	Open-label, long-term, efficacy, safety, and tolerability extension study using ACT-385781A in the t ...	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL			14	BOTH	3	Phase 3	NULL
6	NCT02276872 (ClinicalTrials.gov)	December 18, 2014	21/10/2014	Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to ...	A Multicenter, Open-Label, 24-Week, Uncontrolled Study to Evaluate the Safety, Tolerability, and Pha ...	PAH	Drug: oral treprostinil	United Therapeutics	NULL	Completed	7 Years	17 Years	All	32	Phase 2	United States
7	JPRN-JapicCTI-142721	01/9/2014	27/11/2014	ACT-385781A for PAH pediatric patients	Prospectiove, single-arm, Open-label, multi-center study to assess the efficacy, safety, and tolerab ...	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL			14	BOTH	3	Phase 3	NULL
8	JPRN-JapicCTI-132142	01/4/2013	03/06/2013	ACT-385781A PAH Post-marketing study	A Post-marketing, Open-label-study ACT-385781A in patients with pulmonary arterial hypertension	Pulmonary arterial hypertension (PAH)	Intervention name : ACT-385781A INN of the intervention : Epoprostenol Dosage And administration of th ...	Actelion Pharmaceuticals Japan Ltd.	NULL		20		BOTH	5	Phase 4	NULL
9	EUCTR2010-018320-10-ES (EUCTR)	26/12/2011	21/11/2011	An extension of study AC-066A301 to investigate safety and tolerability of the study medication (epo ...	An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A ...	Hipertension Arterial Pulmonar MedDRA version: 14.0;Level: PT;Classification code 10064911;Term: Pul ...	Trade Name: Epoprostenol for injection Product Name: Epoprostenol for injection Product Code: ACT-385781 ...	ACTELION Pharmaceuticals Ltd	NULL	Not Recruiting			Female: yes Male: yes	40		France;Canada;Belgium;Spain;Netherlands;Italy
10	EUCTR2011-002943-92-NL (EUCTR)	07/11/2011	22/08/2011	Study of a new thermostable formulation of Flolan™ to treat Pulmonary Arterial Hypertension (PAH)	A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation ...	pulmonary arterial hypertension (PAH) MedDRA version: 14.1;Level: PT;Classification code 10064911;Te ...	Trade Name: FLOLAN™ and Glycine Diluent Product Name: FLOLAN™ and Glycine Diluent Product Code: 4AU76 I ...	GlaxoSmithKline Research and Development Limited	NULL	Not Recruiting			Female: yes Male: yes	20		United States;Canada;Netherlands

First Previous1 2 3 4Next Last